SomaGenics, Inc. specializes in developing novel RNA-centered approaches to address unmet life science research and medical needs. Our core competencies include RNA molecules as therapeutic agents, drug targets and biomarkers as well as RNA analysis tools. SomaGenics has a proven track record of original research and publication as well as applied development and commercialization.
SomaGenics has raised over $25 million in federal grant funding from agencies such as NIH, NSF, NASA and DARPA and maintains an impressive intellectual property portfolio covering our nucleic acid-based technologies for life science research, therapeutics and diagnostics.
The company has enjoyed fruitful collaborations with a number of top academic institutions as well as industry, including Stanford University, MIT, Princeton University, City of Hope, Harvard Medical School, UC Berkeley, UCLA, UC San Francisco, UC Santa Cruz and companies such as Roche, Tekmira and Takara Bio USA.
SomaGenics has raised over $25 million in federal grant funding from agencies such as NIH, NSF, NASA and DARPA and maintains an impressive intellectual property portfolio covering our nucleic acid-based technologies for life science research, therapeutics and diagnostics.
The company has enjoyed fruitful collaborations with a number of top academic institutions as well as industry, including Stanford University, MIT, Princeton University, City of Hope, Harvard Medical School, UC Berkeley, UCLA, UC San Francisco, UC Santa Cruz and companies such as Roche, Tekmira and Takara Bio USA.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
1997
Main Therapeutic Focus:
Tools/Drug Development Support Tech
Lead Product in Development:
HASL-free NGS library platform (the subject of our BIO presentation)
The company sells its proprietary miR-ID and miR-Direct small RNA detection products and licensed its RNA-seq patents to its spinout company RealSeq Biosciences, which has commercialized them.
Development Phase of Primary Product:
Other/Not Applicable
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
